Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark G Lebwohl

Showing results (91-100 of 209) with videos related to

Pageof 21
Sort By:
Journal of the American Academy of Dermatology|August 12, 2009
Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis FoundationMisha Rosenbach, Sylvia Hsu, Neil J Korman, et al.
Journal of the American Academy of Dermatology|November 25, 2023
Nail psoriasis and nail lichen planus: Updates on diagnosis and managementJonathan K Hwang, Chander Grover, Matilde Iorizzo, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis RegistryMark G Lebwohl, Rose Anne Medeiros, Rachel H Mackey, et al.
American Journal of Clinical Dermatology|September 8, 2019
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II StudyMark G Lebwohl, Andrew Blauvelt, Alan Menter, et al.
F1000Research|December 5, 2017
Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activityAnjali S Vekaria, Patrick M Brunner, Ahmad I Aleisa, et al.
Journal of Drugs in Dermatology : JDD|December 31, 2004
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasisAlice B Gottlieb, Kenneth B Gordon, Mark G Lebwohl, et al.
Dermatology and Therapy|August 1, 2024
Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature SearchLluís Puig, Hideki Fujita, Diamant Thaçi, et al.
Dermatology and Therapy|May 24, 2024
Treatment Discontinuation in Patients with Psoriasis Treated with Biologics: A Retrospective Analysis of German Health Claims DataAndreas Pinter, Ahmed M Soliman, Karina C Manz, et al.
Dermatology and Therapy|September 22, 2021
Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic DermatitisBob Geng, Adelaide A Hebert, Liza Takiya, et al.
Dermatology and Therapy|August 11, 2021
Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic DermatitisBob Geng, Adelaide A Hebert, Liza Takiya, et al.
Pageof 21

Showing results (91-100 of 209) with videos related to

Sort By:
Pageof 21
Journal of the American Academy of Dermatology|August 12, 2009
Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis FoundationMisha Rosenbach, Sylvia Hsu, Neil J Korman, et al.
Journal of the American Academy of Dermatology|November 25, 2023
Nail psoriasis and nail lichen planus: Updates on diagnosis and managementJonathan K Hwang, Chander Grover, Matilde Iorizzo, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 19, 2024
Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis RegistryMark G Lebwohl, Rose Anne Medeiros, Rachel H Mackey, et al.
American Journal of Clinical Dermatology|September 8, 2019
Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II StudyMark G Lebwohl, Andrew Blauvelt, Alan Menter, et al.
F1000Research|December 5, 2017
Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activityAnjali S Vekaria, Patrick M Brunner, Ahmad I Aleisa, et al.
Journal of Drugs in Dermatology : JDD|December 31, 2004
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasisAlice B Gottlieb, Kenneth B Gordon, Mark G Lebwohl, et al.
Dermatology and Therapy|August 1, 2024
Current Treatments for Generalized Pustular Psoriasis: A Narrative Summary of a Systematic Literature SearchLluís Puig, Hideki Fujita, Diamant Thaçi, et al.
Dermatology and Therapy|May 24, 2024
Treatment Discontinuation in Patients with Psoriasis Treated with Biologics: A Retrospective Analysis of German Health Claims DataAndreas Pinter, Ahmed M Soliman, Karina C Manz, et al.
Dermatology and Therapy|September 22, 2021
Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic DermatitisBob Geng, Adelaide A Hebert, Liza Takiya, et al.
Dermatology and Therapy|August 11, 2021
Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic DermatitisBob Geng, Adelaide A Hebert, Liza Takiya, et al.
Pageof 21